Clinical Investigation

Kidney International (1997) 36, 120–126; doi:10.1038/ki.1989.170

Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia

Pablo Ureña1, Carlo Basile1, Gilles Grateau1, Bernard Lacour1, Anne Vassault1, Agnès Bourdeau1, Roger Bourdon1, Claude Dubost1, Johanna Zingraff1 and Tilman Drüeke1

1Département de Néphrologie, INSERM U90, CNRS UA 583 and Laboratoire de Biochimie A, Hôpital Necker-Enfants Malades; Laboratoire de Biochimie, Hôpital Fernand Widal and Service de Chirurgie Viscérale, Hôpital Saint-Louis, Paris, France

Correspondence: Dr Tilman Drüeke, Département de Néphrologie, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France.

Received 16 June 1988; Revised 13 December 1988; Accepted 7 February 1989.

Top

Abstract

Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia. Parathyroidectomy (PTx) is indicated in hemodialysis (HD) patients who have severe osteitis fibrosa unresponsive to vitamin D therapy or in whom the latter treatment is contraindicated. Immediately after PTx, plasma immunoreactive parathyroid hormone, calcium and phosphorus concentrations decline abruptly. However, little is known in such patients about the short-term effects of PTx on plasma alkaline phosphatase (AP) activity and plasma aluminum (Al) levels. The present, preliminary study was performed to determine such parameters in 37 HD patients, and to correlate them with data of bone histology. Mean plasma AP activity started to increase after PTx from day 4 onwards. Thus, AP values significantly higher than pre-PTx values were observed at day 7 and 14 (415 plusminus 54 vs. 619 plusminus 77 and 749 plusminus 83 IU/liter, means plusminus SEM; N = 37; P < 0.05 and 0.001, respectively). This increase, in the absence of changes in liver function, was mainly due to the bone-specific iso-AP. Moreover, the degree of increase in plasma AP activity was higher in the subgroup with negative (group I, 21 patients) than in that with positive bone Al staining (group II, 16 patients). However, plasma osteocalcin (BGP) did not change after PTx (N = 8). Basal plasma Al levels were significantly higher in group II both before and two weeks after surgery. The mean increase of plasma Al level after a deferoxamine (DFO) infusion test was higher in group II than in group I both before (10.8 plusminus 1.6, vs. 4.6 plusminus 0.8 mumol/liter, P < 0.001) and after PTx (6.5 plusminus 1.5, vs. 2.6 plusminus 0.6 mu;mol/liter, P < 0.01). Moreover, the mean increase of plasma Al after DFO was significantly higher before than after PTx in both groups. In conclusion, this study in uremic patients shows the occurrence, immediately after PTx, of both a consistent increase in plasma AP activity (probably reflecting flare up of osteoblastic activity) and a significant decrease of tissue Al mobilization under DFO chelation. Even though hypotheses have been formulated to explain these findings, further studies are needed to understand their relation with skeletal changes in response to parathyroid gland removal.

Top

References

  1. Coburn JW, Slatopolsky E: Vitamin D, parathyroid hormone, and renal osteodystrophy, in chapter 39, The Kidney, edited by Brenner BM Rector FC Jr, third edition, Philadelphia, Saunders, 1986, p. 1657
  2. Felsenfeld AJ, Gutman RA, Llach F, Harrelson JM, Wells SA: Postparathyroidectomy hypocalcemia as an accurate indicator of preparathyroidectomy bone histology in the uremic patient. Miner Electrol Metab 10:166–172, 1984
  3. Diaz-Buxo JA, Geissinger WT, Walker PJ, Chandler JT, Farmer CD, Holt KL, Wolfe P: Total parathyroidectomy and autotransplantation. Clin Nephrol 16:276–282, 1981
  4. De Francisco AM, Ellis HA, Owen JP, Cassidy MJD, Farndons JR, Ward MK, Kerr DNS: Parathyroidectomy in chronic renal failure. Quart J Med 218:289–315, 1985
  5. Clair F, Leenhardt L, Bourdeau A, Zingraff J, Robert D, Dubost C, Sachs EF, Drueke T: Effect of calcitriol in the control of plasma calcium after parathyroidectomy. Nephron 46:18–22, 1987
  6. Andress D, Ott SM, Maloney NA, Sherrard DJ: Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312:468–73, 1985 | PubMed | ISI | ChemPort |
  7. De Vernejoul MC, Marchais S, London G, Morieux C, Bielakoff J, Miravet L: Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients. Kidney Int 27:785–791, 1985 | Article |
  8. Malluche HH, Faugere MC: Aluminum-related bone disease. Blood Purif 6:1–15, 1988
  9. Milliner DS, Ott SM, Nebeker HG, Andress DL, Sherrard DJ, Alfrey AC, Slatopolsky E, Coburn JW: Deferoxamine infusion test for diagnosis of aluminum-related osteodystrophy. Ann Int Med 101:775–780, 1984
  10. Karsenty G, Vigneron N, Jorgetti V, Fauchet M, Zingraff J, Drueke T, Cournot-Witmer G: Value of 99mTc-methylene diphosphonate bone scan in renal osteodystrophy. Kidney Int 29:1058–1065, 1986 | Article | ChemPort |
  11. Slatopolsky E: The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 31:842–854, 1987 | Article | PubMed |
  12. Bourdeau A, Plachot JJ, Cournot-Witmer G, Pointillard A, Balsan S, Sachs C: Parathyroid response to aluminum in vitro: ultrastructural changes and PTH release. Kidney Int 31:15–24, 1987 | Article | PubMed | ISI | ChemPort |
  13. Nebeker HG, Andress DK, Milliner DS, Ott SM, Alfrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW: Indirect methods for the diagnosis of aluminum bone disease: Plasma aluminum, the desferoxamine infusion test, and serum iPTH. Kidney Int (29Suppl 18):S96–S99, 1986
  14. Cournot-Witmer G, Zingraff J, Plachot JJ, Escaig F, Le-Fevre R, Boumati P, Bourdeau A, Garabedian M, Galle P, Bourdon R, Drueke T, Balsan S: Aluminum localization in bone from hemodialyzed patients: Relationship to matrix mineralization. Kidney Int 20:375–385, 1981 | PubMed | ChemPort |
  15. Maloney NA, Ott SM, Alfrey AC, Miller NL, Coburn JW, Sherrard DJ: Histological quantitation of aluminum in iliac bone from patients with renal failure. J Lab Clin Med 99:206–216, 1982 | PubMed | ISI | ChemPort |
  16. Whitby LG, Moss DW: Analysis of heat inactivation curves of alkaline phosphatase isoenzymes in serum. Clin Chim Acta 59:361–367, 1975
  17. Preece MA, O'Riordan JLH, Lawson DEM, Kodicek E: A competitive protein binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta 54:235–242, 1974
  18. Robinson RA: Bone tissue: Composition and function. Johns Hopkins Med J 145:10–24, 1979
  19. Ritz E, Krempien B, Mehls O, Malluche H: Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int 4:116–127, 1973
  20. Marie PJ, Travers R: Continuous infusion of 1,25 dihydroxyvitamin D3 stimulates bone turnover in the normal young mouse. Calcif Tissue Int 35:418–425, 1983
  21. Teitelbaum SL, Bullough PG: Pathophysiology of bone and joint disease. Am J Pathol 96:283–354, 1979
  22. Brasier AR, Nussbaum SR: Hungry bone syndrome: Clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 84:654–660, 1988
  23. Manolagas SC, Burton DW, Deftos LJ: 1,25-dihydroxyvitamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem 256:7115–7117, 1981
  24. Farley JR, Baylink DJ: Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metabolism 35:563–571, 1986
  25. Parfitt AM: The coupling of bone formation to bone resorption: A critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4:1–6, 1982
  26. Plachot JJ, Cornot-Witmer G, Halpern S, Mendes V, Bourdeau A, Fritsch J, Bourdon R, Drueke T, Galle P, Balsan S: Bone ultrastructure and x-ray microanalysis of aluminum-intoxicated hemodialyzed patients. Kidney Int 25:796–803, 1984
  27. Mayor G, Keiser JA, Makdani D, Ku PD: Aluminum adsorption and distribution: Effect of parathyroid hormone. Science 197:1187–1189, 1977
  28. Mayor GH, Sprague SM, Hourani MR, Sanchez TV: Parathyroid hormone-mediated aluminum deposition and egress in the rat. Kidney Int 17:40–44, 1980
  29. Drüeke T, Lacour B, Touam M, Basile C, Bourdon R: Oral aluminum administration to uremic, hyperparathyroid, or vitamin D-supplemented rats. Nephron 39:10–17, 1985
  30. Hirschberg R, von Herrath D, Voss R, Bossaller W, Mauelshagen U, Pauls A, Schaefer K: Organ distribution of aluminium in uremic rats: Influence of parathyroid hormone and 1,25-dihydroxy vitamin D3. Miner Electrol Metab 11:106–110, 1985
  31. Fanti P, Smith AJ, Price PA, Reitz E, Malluche HH: Effects of parathyroidectomy on circulating levels of 1 alpha, 25-dihydroxy-vitamin D and bone Gla protein in dialyzed patients. J Clin Endocr Metab 62:869–873, 1986
  32. Malluche H, Faugere MC, Fanti P, Price PA: Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26:869–874, 1984 | Article | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT